Although tremendous efforts have been made to delay AD progression as well as ameliorate and cure AD symptoms, only four cholinesterase inhibitors (donepezil, galantamine, reivastigmine, and tacrine, which is rarely prescribed because of its associated side effects, especially liver damage) and an NMDAR antagonist (memantine) have been approved by the U.S. Food and Drug Administration for AD treatment. Here, BCHE is linked to Alzheimer disease.